CIK 0001035354 · Non-accelerated filer<br>Smaller reporting company
Eloxx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ELOX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 841368850
- Phone
- 781-577-5300
- Business address
- P.O. BOX 274, ARLINGTON, MA, 02476
- Former names
- Sevion Therapeutics, Inc., SENESCO TECHNOLOGIES INC, NAVA LEISURE USA INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-07-30 | Belloff Neil S. COO, GENERAL COUNSEL &CORP SEC | Option exercise | +1,563 | 33,158 | ||
| 2021-07-30 | Belloff Neil S. COO, GENERAL COUNSEL &CORP SEC | Shares withheld for taxes | −459 | $1.32 | $606 | 32,699 |
| 2021-07-30 | Belloff Neil S. COO, GENERAL COUNSEL &CORP SEC | Option exercise · Restricted Stock Units | −1,563 | 9,375 | ||
| 2021-05-25 | Belloff Neil S. COO, GENERAL COUNSEL &CORP SEC | Option exercise | +6,250 | 33,430 | ||
| 2021-05-25 | Belloff Neil S. COO, GENERAL COUNSEL &CORP SEC | Shares withheld for taxes | −1,835 | $1.39 | $3K | 31,595 |
| 2021-05-25 | Belloff Neil S. COO, GENERAL COUNSEL &CORP SEC | Option exercise · Restricted Stock Units | −6,250 | 68,750 | ||
| 2021-05-19 | Walts Alan Edmund Director | Grant or award · Stock Option (Right to Buy) | +3,334 | 3,334 | ||
| 2021-05-19 | PAREKH RAJESH B Director | Grant or award · Stock Option (Right to Buy) | +3,334 | 3,334 | ||
| 2021-05-19 | Nussbaum Ran Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-05-19 | Avnur Zafrira Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-05-19 | Kariv Tomer Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-05-19 | Veinrib Gadi Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-05-19 | Seehra Jasbir Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-05-19 | Rubin Steven D Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-05-18 | MODUR VIJAY HEAD OF R&D | Grant or award · Stock Options (Right to Buy) | +496,204 | 496,204 | ||
| 2021-05-18 | Aggarwal Sumit PRESIDENT AND CEO | Grant or award · Stock Options (Right to Buy) | +992,409 | 992,409 | ||
| 2021-05-13 | PAREKH RAJESH B Director | Purchase | +84,776 | $1.35 | $114K | 171,807 |
| 2021-05-13 | PAREKH RAJESH B Director | Purchase | +2,381,890 | $1.35 | $3.2M | 4,827,129 |
| 2021-05-13 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Purchase | +1,280,624 | $1.35 | $1.7M | 1,791,470 |
| 2021-05-13 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Purchase | +2,630,487 | $1.35 | $3.6M | 3,679,797 |
Page 5 of 11 · 206 trades